FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
1-Year Return
24.36%
This Quarter Return
+13.36%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$371M
AUM Growth
+$13.9M
(+3.9%)
Cap. Flow
-$14M
Cap. Flow
% of AUM
-3.78%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
4
Closed
1
Top Buys
No buys this quarter
Top Sells
| 1 |
Quantum-Si Incorporated
QSI
|
$6.25M |
| 2 |
Nurix Therapeutics
NRIX
|
$4.48M |
| 3 |
HLTH
Cue Health Inc. Common Stock
HLTH
|
$1.7M |
| 4 |
Aclaris Therapeutics
ACRS
|
$1.27M |
| 5 |
Pharvaris
PHVS
|
$332K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KNTE
1
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $122M | 32.84% |
9,671,643
| – | – |
|
2
Lyell Immunopharma
LYEL
$233M
| $86.6M | 23.32% |
664,109
| – | – |
|
|
3
Pharvaris
PHVS
$1.48B
| $71.8M | 19.32% |
3,246,926
-15,000
| -0.5% | -$332K |
|
|
4
Aclaris Therapeutics
ACRS
$227M
| $39.2M | 10.56% |
2,808,034
-91,000
| -3% | -$1.27M |
|
5
Kura Oncology
KURA
$713M
| $33.9M | 9.13% |
1,849,947
| – | – |
|
|
6
Nurix Therapeutics
NRIX
$758M
| $8.58M | 2.31% |
677,143
-353,655
| -34% | -$4.48M |
|
|
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
| $5.27M | 1.42% |
1,787,094
| – | – |
|
|
8
Quantum-Si Incorporated
QSI
$219M
| $4.11M | 1.11% |
1,771,249
-2,692,370
| -60% | -$6.25M |
|
|
HLTH
9
DELISTED
Cue Health Inc. Common Stock
HLTH
| – | – |
-263,578
| Closed | -$1.7M |
|